Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Contributed by: Business Wire

Logo

Images

Business Wire associated0

Business Wire associated1

Business Wire embedded0

Tags

Pharmaceutical

Health

Neurology

Clinical Trials

Merz Therapeutics

More Like This

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao

Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Merz Therapeutics Expands Presence with New Affiliate in Poland

PR Newswire associated0

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine